Sípek A, Gregor V, Velebil P, Horácek J, Masátová D, Svetnicová K
Ustav pro péci o matku a díte, Praha.
Ceska Gynekol. 2004 Dec;69 Suppl 1:33-41.
To process the results on the incidence of birth defects in the children of mothers using medicines in the first trimester of pregnancy in the Czech Republic during 1996-2002.
A retrospective analysis of data from the National Register of birth Defects in the Czech Republic.
The data from the nationwide register of birth defects administrated in the Institute of Health Information and Statistics of the Czech Republic for the period 1996-2002 were used for the study. The data on the incidences of selected types of birth defects identified in children born to mothers using medicines in the first trimester of pregnancy were compiled and an analysis of these medicines was carried out in relation to the diagnosed types of birth defects. The data on healthy children born to mothers using medicines during the 1st trimester of pregnancy were used as the control sample.
In our retrospective analysis covering the years 1996-2002, a total of 1,146 birth defects were identified in children of women using medication in the 1st trimester of pregnancy and a total of 891 children affected in this way were identified.
The study presents the updated results of these analyses based on nationwide registration of birth defects for a seven-year period. It analyses the types of birth defects in the children of women using medication in the 1st trimester of pregnancy and the types of medicines used by these women. In our study, we have found a significantly higher incidence in the population of the children born to women using medicines in the 1st trimester of pregnancy in several cases. From among the group of cleft defects affecting the central nervous system, this concerns for example anencephalia and spina bifida, as well as congenital hydrocephalus, anophthalmy/microphthalmy, auricle abnormalities and limb reduction deformities. From these results that we produced, it is of course not possible to draw significant conclusions with a clinical impact. However, pregnant women should avoid any medicines in the first trimester of pregnancy, except for those cases, which are strictly indicated from the medical point of view and which are recognised as reasonably safe. As concerns the use of other medicines, their genetic and teratogenic risk should be assessed comprehensively by a specialised clinical geneticist on a case-by-case basis.
对1996 - 2002年捷克共和国孕期头三个月使用药物的母亲所生子女的出生缺陷发生率结果进行处理。
对捷克共和国国家出生缺陷登记处的数据进行回顾性分析。
使用捷克共和国卫生信息与统计研究所管理的1996 - 2002年全国出生缺陷登记处的数据进行研究。收集孕期头三个月使用药物的母亲所生子女中选定类型出生缺陷的发生率数据，并针对已诊断的出生缺陷类型对这些药物进行分析。将孕期头三个月使用药物的母亲所生健康儿童的数据用作对照样本。
在我们涵盖1996 - 2002年的回顾性分析中，孕期头三个月使用药物的女性所生子女中总共发现1146例出生缺陷，总共确定891名儿童受此影响。
该研究呈现了基于全国七年出生缺陷登记的这些分析的最新结果。它分析了孕期头三个月使用药物的女性所生子女的出生缺陷类型以及这些女性使用的药物类型。在我们的研究中，我们发现在某些情况下，孕期头三个月使用药物的女性所生子女群体中的发生率显著更高。在影响中枢神经系统的腭裂缺陷组中，这涉及例如无脑儿和脊柱裂，以及先天性脑积水、无眼/小眼、耳廓异常和肢体减少畸形。从我们得出的这些结果当然无法得出具有临床影响的重大结论。然而，孕妇在孕期头三个月应避免使用任何药物，除非是从医学角度严格指示且被认为合理安全的情况。至于使用其他药物，应由专业临床遗传学家根据具体情况全面评估其遗传和致畸风险。
